FDA approves Roche’s Evrysdi for use in babies under two months with spinal muscular atrophy (SMA)
The Pharma Data
MAY 31, 2022
More than 5,000 patients have now been treated worldwide with Evrysdi in clinical trials, compassionate use or real-world settings. Roche leads the clinical development of Evrysdi as part of a collaboration with the SMA Foundation and PTC Therapeutics. Jude Children’s Research Hospital.
Let's personalize your content